CN101554406A - Extraction process and formulation of mulberry cortex hypoglycemic medicinal active material - Google Patents
Extraction process and formulation of mulberry cortex hypoglycemic medicinal active material Download PDFInfo
- Publication number
- CN101554406A CN101554406A CNA2009100987597A CN200910098759A CN101554406A CN 101554406 A CN101554406 A CN 101554406A CN A2009100987597 A CNA2009100987597 A CN A2009100987597A CN 200910098759 A CN200910098759 A CN 200910098759A CN 101554406 A CN101554406 A CN 101554406A
- Authority
- CN
- China
- Prior art keywords
- raw material
- material powder
- extraction
- alcohol
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了桑树皮降糖药用活性物质提取工艺及其配方，其工艺流程为：A.采摘、B.干燥、C.粉碎、D.加入酒精然后超声波提取、E.将D步骤的提取液产生的提取液旋蒸去除酒精喷雾干燥，得到含有总黄酮的原料粉1、F.将D步骤的产生的滤渣加入酒精，然后超声波继续提取、G.将F步骤产生的提取液喷雾干燥得到含有DNJ类生物碱的原料粉2、H.将F步骤产生的滤渣酒精完全挥发后，加入纯水提取、I.将H步骤的提取液收集上清液，用酒精沉淀烘干得到含有多糖类的原料粉3。按上述步骤提取的活性物质配方为：原料粉1、原料粉2、原料粉3按1∶1－3∶2－4进行配比。本发明可以改善因糖尿病并发症导致的肝、肾功能损伤。
The invention discloses an extraction process and formula of mulberry bark hypoglycemic medicinal active substances. The process flow is: A. picking, B. drying, C. crushing, D. adding alcohol and then ultrasonic extraction, E. extracting the D step The extract produced by the solution is rotary evaporated to remove alcohol and spray dried to obtain raw material powder containing total flavonoids. 1. F. Add alcohol to the filter residue produced in step D, and then continue to extract with ultrasonic waves. Raw material powder containing DNJ alkaloids 2, H. After the filter residue alcohol produced in step F is completely volatilized, add pure water to extract, I. collect the supernatant from the extract of step H, and dry it with alcohol precipitation to obtain polysaccharide-containing Class raw material powder3. The formula of the active substance extracted according to the above steps is: raw material powder 1, raw material powder 2, raw material powder 3 according to the ratio of 1:1-3:2-4. The invention can improve liver and kidney function damage caused by diabetes complications.
Description
Technical field
The present invention relates to the extraction process of a kind of plant (mulberry) skin three class active medicinal matters and the active medicinal matter proportioning prescription of acquisition, specifically, relate to the extraction process and the proportioning prescription thereof of total flavones in the Cortex Mori, polysaccharide, DNJ Alkaloid.Be mainly used in and reduce the diabetics fasting glucose, improve patient's carbohydrate tolerance, reduce the whole blood glycolated hemoglobin, promote the beta Cell of islet function, significantly improve liver, the renal dysfunction that causes because of diabetic complication.
Background technology
Diabetes be a kind of because defect of insulin secretion and (or) its biological action obstacle causes is the multisystem metabolism disorder disease of feature with the hyperglycemia.According to the pathogenesis difference, be divided into type i diabetes (insulin-dependent) and type ii diabetes (non-insulin-depending type), the latter accounts for more than 85% of diabetes sum.The drug main that is used for the treatment of diabetes at present will be divided into chemical antidiabetic drug (as sulfonylurea, biguanides, insulin type and Alpha-glucosidase inhibitor etc.) (Yan Li, the field is quiet. the progress of hypoglycemic medicine [J], progress, 2008,5 (2): 22-24) and pure Chinese medicine antidiabetic drug (JINQI JIANGTANG PIAN, SHENQI JIANGTANG sheet/granule/capsule, TANGMAIKANG KELI, JIANGTANGSHU JIAONANG, TANGNIAOLE JIAONANG, YUQUAN WAN, good wine quench one's thirst granule etc.) (Yang Xuanxuan. Chinese medicine blood sugar lowering Advance on Pharmacological Activities [J], the Hebei traditional Chinese medical science, 2004,26 (4): 305-308).The untoward reaction of first three class chemical hypoglycemic medicine is bigger, can cause ill symptomses such as hepatic injury, hypoglycemia and edema, acarbose (glucobay (acarbose)) is as a kind of Alpha-glucosidase inhibitor, thereby mainly by slowing down the absorption reduction postprandial hyperglycemia (Yang Bo of intestinal to carbohydrate, Liu Xinrong. research of oral antidiabetic thing and development progress [J]. Chinese Medicine information, 1996; 5 (6): 337-339), but because this medicine has certain inhibitory action to α-Dian Fenmei, the carbohydrate of not digesting and assimilating enters large intestine with the form of oligosaccharide, cause sugared malabsorption, thereby cause stronger intestinal side effect (Yan Li such as aerofluxus, abdominal distention, diarrhoea, the field is quiet. the progress of hypoglycemic medicine [J], progress, 2008,5 (2): 22-24), (Wang Mei, acarbose cause hepatic injury 1 example [J] pharmacovigilance also can to cause liver dysfunction simultaneously, 2008,5 (2): 121-121; Hsiao SH, Liao LH, Cheng PN, et al.Hepatotoxicity associatedwith acarbose therapy[J] Annals of Pharmacotherapy, 2006,40 (1): 151-154; Yao Jun translates selected passages. the liver toxicity [J] relevant with acarbose class medicine. and Chinese diabetes magazine, 1999,7 (2): 125).Though and at present the pure Chinese medicine antidiabetic drug relative safety on the China market is higher, curative effect a little less than, onset is slower.
Folium Mori since ancient times just as the treatment diabetes prescription be used for clinical (institute of Materia Medica,Chinese Academy of Medical Sciences. Chinese medicinal herbal [M] Beijing: People's Health Publisher, 1960), modern pharmacology discovers that having hypoglycemic composition in the Folium Mori mainly contains polysaccharide, flavone, saponin, terpenoid, number of chemical structure types such as alkaloid, big (the Chen Fujun of polysaccharide proportion in sugar-lowering components wherein, Lu Jun, Zhang Yongyu. the pharmacological research of Mulberry (1)-white mulberry leaf blood-sugar-reducing effective components is to the glycometabolic influence of diabetic animal [J], Shenyang Pharmaceutical University's journal, 1996,13 (1): 24-26), Folium Mori total flavonoids then can have significant hypoglycemic activity by inhibition rat small intestine disaccharidase activity, and (Yu Ling Oriolus chinensis diffusus Lee is to Rong Fangxiao, Folium Mori total flavonoids is to the inhibitory action [J] of diabetes rat small intestinal disaccharidase, China's endocrine metabolism magazine, 2002,18 (4): 313-315; Former love is red, Huang Zhe, Ma Jun, Jiang Xiaofeng, Kong Xiantao, Li Su, the extraction of flavones in mulberry leaves and the research of blood sugar reducing function [J] thereof, Chinese herbal medicine, 2004,35 (11): 1242-1243); And 1-DNJ, N-Me-DNJ, multiple alkaloid such as GAL-DNJ and fagomine with blood sugar decreasing effect, also just more and more receive domestic and international medical investigator's concern, wherein fagomine may bring into play blood sugar reducing function by the release that increases insulin, the DNJ Alkaloid is tentatively thought inhibitor (the Naoki Asano N.Naturally OccurringIminosugars and Related Compounds:Structure of alpha-Glucosidase, Distribution, andBiological Activity.Current Topics in Medicinal Chemistry, 2003,3:471-475; Sun Lian, Meng Lei, the Yan is superfine. the blood-sugar decreasing active of Folium Mori and pharmacological action [J] Chinese herbal medicine, 2002,33 (5): 471-473; The side is known. and the Folium Mori leachate is to diabetes model rat hypoglycemic activity preliminary observation [J] Zhejiang medical science, 1999,21 (4): 218).
Summary of the invention
The object of the present invention is to provide Cortex Mori three class active medicinal matter (total flavones, polysaccharide, the DNJ Alkaloid) the extraction process and the active medicinal matter of acquisition are filled a prescription according to a certain percentage, the present invention mainly is the mutual synergism by three class active medicinal matters, not only can reduce the diabetics fasting glucose, improve carbohydrate tolerance, the more important thing is and to reduce patient's whole blood glycolated hemoglobin, promote the beta Cell of islet function, significantly improve the liver that causes because of diabetic complication, renal dysfunction, and can effectively solve existing metformin and cause patient's sugar malabsorption easily, thereby cause aerofluxus, abdominal distention, the problem of the intestinal side effect that diarrhoea etc. are stronger.
In order to solve the problems of the technologies described above, the present invention is achieved by the following technical solutions: the extraction process flow process of Cortex Mori active medicinal matter is:
A. pluck: pluck Cortex Mori, the annual mulberry summer is cut down May phase to June;
B. dry: with the Cortex Mori drying of plucking, baking temperature is not more than 60 ℃;
C. pulverize: grinding particle size 10 order to 30 orders;
D. add ethanol, then ultrasonic extraction: alcohol concentration 90-100%, the weight ratio of feed liquid is 1: 5-10,
30 minutes to 2 hours extraction time, extract 20-60 ℃ of temperature, ultrasonic power: 900-1100W obtains extracting solution and filtering residue;
The extracting solution that produces during E. with the D step revolves and boils off except that ethanol, after concentrating, and freezing or spray drying,
To the raw material powder 1 that contains total flavones, or directly to adopt nitrogen be the raw material powder 1 that the closed cycle spray drying of medium obtains containing total flavones;
F. the filtering residue with the generation of D step adds ethanol, and ultrasound wave continues to extract then: alcohol concentration 50-70%, and the weight ratio of feed liquid is 1: 5-10,30 minutes to 2 hours extraction time, extract temperature: 20-60 ℃, ultrasonic power: 900-1100W obtains extracting solution and filtering residue;
G. the extracting solution that the F step is produced revolves and boils off except that ethanol reconcentration, centrifugal collection supernatant, supernatant
Liquid adsorbed 5-10 minute with strongly acidic cation-exchange, and after the pure water rinsing roguing, resin is collected the freezing or spray drying of eluent with the ammonia eluting of 0.2-0.4mol/L, obtains containing the raw material powder 2 of DNJ Alkaloid.
H. after the filtering residue ethanol that the F step is produced volatilizees fully, add pure water and extract, the weight ratio of feed liquid is 1:
5-8 extraction time 2-4 hour, extracts temperature: 90-100 ℃;
I. the extracting solution of H step is revolved that inspissation contracts, centrifugal collection supernatant, supernatant is with final concentration 70-80% alcohol precipitation, and collecting precipitation is pulverized after the 60-70 ℃ of oven dry, obtains containing the raw material powder 3 of polysaccharide.
The prescription that obtains the Cortex Mori active medicinal matter according to above-mentioned technology is, with raw material powder 1, raw material powder 2, raw material powder 3 in 1: the ratio of 1-3: 2-4 is carried out proportioning, fully mix fair after, by the tablet machine tabletting promptly.
Preferably, described A step Cortex Mori plucking time is annual late May; Described C step grinding particle size is 20 orders; The alcohol concentration that described D step and F step add is respectively 93%, 66%, and extraction time all is 1 hour, extracts temperature and all is 40 ℃; The ratio of described raw material powder 1, raw material powder 2, raw material powder 3 is 1: 1.8: 2; Can reach the parameter of optimum efficiency.
Compared with prior art, advantage of the present invention is: the by-product Cortex Mori with sericulture there is a raw material, utilize modern extraction process, extract high-load Alpha-glucosidase inhibitor and had the Mulberry polysaccharide compound that promotes beta Cell of islet reparation, secretion and human body immunity improving function, by the collaborative facilitation between the inhomogeneity active substance, the hypoglycemic medicine that exploitation makes new advances.This product can reduce diabetics fasting glucose, post-prandial glycemia, whole blood glycolated hemoglobin, improve serum insulin levels, and remarkable liver, the renal dysfunction that causes because of diabetic complication that improve, intestinal side effect such as no aerofluxus, abdominal distention, diarrhoea, strongly professional, the good reproducibility of extracting method that technology is simple, set up, and use medical alcohol to extract not only environmental protection, product safety is reliable simultaneously, is suitable for suitability for industrialized production.
Description of drawings
The invention will be further described below in conjunction with accompanying drawing:
Fig. 1 is the process chart of invention;
Fig. 2 adopts the influence comparison diagram of the medicament of this technology and prescription production to the diabetic mice fasting glucose;
Fig. 3 for the medicament two weeks that adopts this technology and prescription and produce after to the comparison diagram that influences of diabetic mice carbohydrate tolerance;
Fig. 4 for back around the medicament administration of adopting this technology and prescription and producing to the comparison diagram that influences of diabetic mice carbohydrate tolerance.
The specific embodiment
Consulting Fig. 1 for the extraction process flow process of Cortex Mori active medicinal matter of the present invention is:
A. pluck: pluck Cortex Mori, annual May;
B. dry: with the Cortex Mori drying of plucking, 50 ℃ of baking temperatures;
C. pulverize: grinding particle size 20 orders;
D. add ethanol, then ultrasonic extraction: alcohol concentration 93%, the weight ratio of feed liquid are 1: 10,1 hour extraction time, extract 40 ℃ of temperature, and ultrasonic power: 1000W obtains extracting solution and filtering residue;
The extracting solution that produces during E. with the D step revolves and boils off except that ethanol, and after concentrating, freezing or spray drying obtains containing the raw material powder 1 of total flavones, or directly to adopt nitrogen be the raw material powder 1 that the closed cycle spray drying of medium obtains containing total flavones;
F. the filtering residue with the generation of D step adds ethanol, and ultrasound wave continues to extract then: alcohol concentration 66%, the weight ratio of feed liquid are 1: 10, and 1 hour extraction time, extract temperature: 40 ℃, ultrasonic power: 1000W obtains extracting solution and filtering residue;
G. the extracting solution that the F step is produced revolves and boils off except that ethanol, reconcentration, centrifugal collection supernatant, supernatant adsorbed 6 minutes with strongly acidic cation-exchange, after the pure water rinsing roguing, the resin ammonia eluting of 0.3mol/L, collect the freezing or spray drying of eluent, obtain containing the raw material powder 2 of DNJ Alkaloid;
H. after the filtering residue ethanol that the F step is produced volatilizees fully, add pure water and extract, the weight ratio of feed liquid is 1: 7,4 hours extraction times, extracts temperature: 100 ℃;
I. the extracting solution of H step is revolved that inspissation contracts, centrifugal collection supernatant, supernatant is with final concentration 75% alcohol precipitation, and collecting precipitation is pulverized after 70 ℃ of oven dry, obtains containing the raw material powder 3 of polysaccharide.
Adopt the raw material powder of above-mentioned explained hereafter to carry out proportioning in 1: 1.8: 2 ratio in raw material powder 1, raw material powder 2, raw material powder 3, fully behind the mixing, by the tablet machine tabletting, every heavily about 0.44 gram, active constituent content: DNJ Alkaloid 〉=9.0%, polyoses content 〉=40.0%, general flavone content 〉=1.0%.Below be that the medicament that adopts this technology and prescription to produce is carried out the pharmacological effect experiment, this experiment is entrusted Zhejiang University of Traditional Chinese Medicine Animal Experimental Study center to finish pharmacodynamics and is detected, utilize the tail vein injection alloxan to set up the mice diabetes model and experimentize, this model is to generally acknowledge diabetes animal model;
1. test objective
Observe to adopt medicament that this technology and prescription produce to blood sugar lowering, carbohydrate tolerance and the blood fat of diabetic mice and the influence of hepatic and renal function, the medicament of producing for this technology and prescription provides preliminary experimental basis to the therapeutical effect of diabetic mice.
2. be subjected to the reagent thing
2.1 trial drug
The medicament tablet raw material that adopts this technology and prescription to produce, shape: pale brown toner end, lot number: 080907, storage procedures: lucifuge, drying, room temperature (below 25 ℃) are preserved, compound method: face with preceding under aseptic condition with 0.9% physiological saline solution to desired concn.
2.2 positive control
Glucobay (acarbose), shape: white tablet, specification: 48/box, the 50mg/ sheet, lot number: 113814, production unit: BeiJing, China Bayer HealthCare Co, storage procedures: lucifuge, drying, room temperature (below 25 ℃) are preserved, compound method: face with preceding under aseptic condition with 0.9% physiological saline solution to desired concn.
3. experimental animal
Cultivars and strains: ICR mice, rank: SPF level, sex: male, body weight: 22-24g, quantity: 160, the source: Shanghai Experimental Animal Center/Shanghai Slac Experimental Animal Co., Ltd. of the Chinese Academy of Sciences [production licence: SCXK (Shanghai) 2007-0005], wherein 150 are used to prepare the diabetic mice model, screening blood glucose is made normal control for 12 in addition 50 of the diabetic mices of 16-24mmol/L.
4. experiment condition
Barrier system experiment receptacle, temperature: 22 ± 1 ℃, humidity: 50-70%, illumination: 150-200Lx, light and shade replaced in 12 hours, noise＜50dB, occupancy permit: SYXK (Zhejiang) 2003-0003.
Drinking-water: the tap water filter sterilization places autoclaved drinking-water bottle freely to drink.
Feedstuff: full nutrition pellet.
Feeding manner: free diet, give competent feedstuff and water in the mice rearging cage, every cage is raised 5 mices, and before the test, every mice is weighed, marker number.
5. reagent and instrument
5.1 reagent and test kit
5.1.1 alloxan, the 10g/ bottle, sigma company product, lot number are 12K1460, compound method: face with preceding and be mixed with the alloxan solution that concentration is 6mg/ml with normal saline;
5.1.2 sucrose, the 500g/ bottle, China Medicine (Group) Shanghai Chemical Reagent Co.,, lot number is 20040205, compound method: face with preceding and be mixed with the sucrose solution that concentration is 0.15g/ml with normal saline;
5.1.3 glycolated hemoglobin (HbAlc) detection kit, 24 person-portions/box are produced by Norway Axis-Shield company, and lot number is 081025-1;
5.1.4 sodium chloride injection, the 250ml/ bottle, content 0.9% is produced by Shapuaisi Pharmaceutical Co., Ltd., Pinghu City, Zhejiang Prov., and lot number is 070401-4;
5.1.5 the blood glucose reagent strip is produced the date of manufacture 20080711 by Johnson Co.;
5.1.6 glutamate pyruvate transaminase (ALT), millet straw transferring enzyme (AST), blood urea nitrogen (BUN), creatinine (CREA), T-CHOL (TC), triglyceride (TG), HDL-C (HDL-c) and low-density lipoprotein cholesterol (LDL-c) test kit, can Diagnostic Technologies Ltd. of DESAY be produced by the Shen, Shanghai, lot number is respectively 10489/47501/2,10384/46681/6,310/039/3,171/021/3,130/029/2,571/035/2,10778/48249/2 and 4930820;
5.1.7 mouse islets element (Insulin) ELISA test kit is by U.S. R﹠amp; D company produces, lot number E0448r.
5.2 instrument and equipment
5.2.1 OneTouch
RThe Ultra blood glucose meter, Johnson (Shanghai) Medical Appliance Co., Ltd.;
5.2.2 the multi-functional microplate reader of VARIOSKAN FLASH, U.S. Thermo company;
5.2.3 7020 type Hitachi automatic clinical chemistry analyzers, HIT;
5.2.4 the multi-functional complete quantitatively special proteins gold mark detector of NycoCard Reader II, Norway Axis-Shield company.
5.2.5 725 types-86 ℃ cryogenic refrigerator U.S. FORMA company;
5.2.6 AG204-electronic analytical balance Switzerland METTLER company.
6. grouping and administration
6.1 dosage and group
6.1.1 normal control group: normal saline 10mlkg
-1
6.1.2 model control group: normal saline 10mlkg
-1
6.1.3 test group
The medicament low dose group that this technology and prescription are produced: the medicament sheet 110mgkg that this technology and prescription are produced
-1
Dosage group in the medicament that this technology and prescription are produced: the medicament sheet 220mgkg that this technology and prescription are produced
-1
The medicament high dose group that this technology and prescription are produced: the medicament sheet 440mgkg that this technology and prescription are produced
-1
Positive controls: glucobay (acarbose) 50mgkg
-1
6.2 route of administration and capacity
Per os is irritated stomach, 10mlkg
-1
7. test method
7.1 diabetic mice Preparation of model and screening
Get body weight and be 150 of the male ICR mouses of 22-24g, fasting be can't help water 16 hours, alloxan is made into the solution of 6mg/ml with 4 ℃ of normal saline, dosage tail vein injection by 60mg/kg is made diabetes model, the test mice fasting be can't help water 10 hours behind the 10d, get the tail vein and get blood and survey blood glucose and weigh, screening blood glucose is used for test at 50 of the diabetic mices of 16-24mmol/l.
7.2 grouping and administration
Get 60 male diabetic mices and be divided into 6 groups at random, be i.e. the medicament low dose group (110mgkg of model control group, this technology and prescription production by blood glucose value and body weight
-1), dosage group (220mgkg in the medicament produced of this technology and prescription
-1), the medicament high dose group (440mgkg that produces of this technology and prescription
-1), positive controls (glucobay (acarbose) 50mgkg
-1), 10 every group, other gets 10 male ICR mouses and makes the normal control group.Each dosage group of medicament that this technology and prescription are produced and positive controls per os are irritated the medicament sheet medicine 0.1ml/10g body weight that stomach gives corresponding this technology and fills a prescription and produce, model control group and normal control group per os are irritated stomach normal saline 0.1ml/10g body weight, once a day, 5 weeks of successive administration.Test mice is weighed weekly, and weekly tail vein is got blood (the test mice fasting be can't help water 10 hours before getting blood), uses OneTouch
RThe Ultra blood glucose meter is measured the fasting blood sugar of mice, carry out a carbohydrate tolerance test respectively in 2,4 weeks of administration, each is organized the mice fasting and can't help water after 16 hours, mouse tail is got blood, measures with blood sugar test paper and respectively organizes blood glucose, and each group gives to be tried accordingly thing, except that the normal control group, all the other respectively organize the sucrose solution 0.2ml/10g of instant orally give 0.15g/ml, measure the blood glucose of giving sugar back 30min, 60min, 120min, calculate area under the blood glucose curve.Mice is got blood after the last administration, measure mice whole blood glycolated hemoglobin with gold mark method, all the other blood separation serum are measured ALT, AST, BUN, CREA, TC, TG, HDL-c, LDL-c biochemical indicator with 7020 full automatic biochemical apparatus, measure the serum insulin level with the ELISA method.
8. observation index
8.1 body weight and fasting glucose;
8.2 area under carbohydrate tolerance blood glucose and the blood glucose curve;
8.3 whole blood glycolated hemoglobin and serum insulin;
8.4 biochemical indicator: ALT, AST, BUN, CREA, CHOL, TG, HDL-c, LDL-c and HDL-c/TC.
9. date processing
Carry out statistical analysis with SPSS11.5 software, (X ± S) expression, measurement data is used t test evaluation result of the test to all data with mean ± standard deviation.
10 result of the tests
10.1 the medicament that this technology and prescription are produced is to the influence of diabetic mice body weight
The medicament that this technology of table 1 and prescription are produced to the influence of diabetic mice body weight (g, X ± s, n=10)
Annotate: compare with the normal control group,
△P＜0.05,
△ △P＜0.01; With model control group comparable group, * P＜0.05, * * P＜0.01.
By table 1 result as seen, normal control group mice body weight in time prolongation and increase, with the normal control group relatively, the model control group body weight fluctuates up and down and increasess slowly, body weight obviously reduces (P＜0.01); Compare with model control group, body weight no significant difference (P＞0.05) between each dosage group of medicament that this technology and prescription are produced and positive controls mice illustrates through long term administration, and the medicament that this technology and prescription are produced does not have obvious toxic-side effects.
10.2 the medicament that this technology and prescription are produced is to the influence of diabetic mice fasting glucose
The medicament that this technology of table 2 and prescription are produced is to the influence (mmolL of diabetic mice fasting glucose
-1, X ± s, n=10)
Annotate: compare with the normal control group,
△P＜0.05,
△ △P＜0.01; With model control group comparable group, * P＜0.05, * * P＜0.01.
By table 2, Fig. 2 result as seen, with the normal control group relatively, model control group mouse blood sugar obviously raise (P＜0.01); Compare with model control group, the medicament high dose group mice that this technology and prescription are produced blood glucose after 1 week of administration obviously reduces (P＜0.01), and the continual and steady fasting glucose (P＜0.05 or P＜0.01) that effectively reduces diabetic mice, and action effect obviously is better than glucobay (acarbose) (50mg/kg) group.
10.3 the medicament that this technology and prescription are produced is to the influence of diabetic mice carbohydrate tolerance
From table 3,4 and Fig. 3,4 results as seen, with the normal control group relatively, the model control group mouse blood sugar all obviously raises (P＜0.01) before and after orally give sucrose, area also obviously raise (P＜0.01) under the blood glucose song; Compare with model control group, the medicament that this technology and prescription are produced is after each 2,4 week of dosage group mice administration, and area all obviously reduces (P＜0.01) under blood glucose after the orally give sucrose and blood glucose song.
The back influence to the diabetic mice carbohydrate tolerance of 2 weeks of medicament administration that this technology of table 3 and prescription are produced (X ± s, n=10)
Annotate: compare with the normal control group,
△P＜0.05,
△ △P＜0.01; With model control group comparable group, * P＜0.05, * * P＜0.01.
The back influence to the diabetic mice carbohydrate tolerance of 4 weeks of medicament administration that this technology of table 4 and prescription are produced (X ± s, n=10)
Annotate: compare with the normal control group,
△P＜0.05,
△ △P＜0.01; With model control group comparable group, * P＜0.05, * * P＜0.01.
10.4 the medicament that this technology and prescription are produced is to the influence of glycolated hemoglobin and insulin in the diabetic mice blood
The medicament that this technology of table 5 and prescription are produced to the influence of glycolated hemoglobin and insulin in the diabetic mice blood (X ± s, n=10)
Annotate: compare with the normal control group,
△P＜0.05,
△ △P＜0.01; With model control group comparable group, * P＜0.05, * * P＜0.01.
From table 5 result as seen, compare with the normal control group, glycolated hemoglobin percentage ratio obviously raises (P＜0.01) in the model control group mouse blood, and insulin level then significantly reduces (P＜0.01); Compare with model control group, glycolated hemoglobin percentage ratio obviously reduces (P＜0.05) in the medicament high dose group mouse blood that this technology and prescription are produced, serum insulin levels then obviously raises (P＜0.05), and does not have significant difference (P＞0.05) with normal group.
10.5 the medicament that this technology and prescription are produced is to the influence of diabetic mice blood fat
From table 6 result as seen, compare with the normal control group, TC, HDL-c and LDL-c obviously raise (P＜0.01) in the model control group mice serum, and HDL-c/TC ratio obviously reduces (P＜0.05), and TG does not have significant change ((P＞0.05)); Compare with model control group, TC, TG and LDL-c do not have significant change (P＞0.05) in each dosage group mice serum of medicament that this technology and prescription are produced, but blood fat has reduction trend, and HDL-c and HDL-c/TC ratio have trend of rising, but does not have significant difference (P＞0.05).
The medicament that this technology of table 6 and prescription are produced to the influence of diabetic mice blood fat (X ± s, n=10)
Annotate: compare with the normal control group,
△P＜0.05,
△ △P＜0.01; With model control group comparable group, * P＜0.05, * * P＜0.01.
10.6 the medicament that this technology and prescription are produced is to the influence of diabetic mice hepatic and renal function
The medicament that this technology of table 7 and prescription are produced to the influence of diabetic mice hepatic and renal function (X ± s, n=10)
Annotate: compare with the normal control group,
△P＜0.05,
△ △P＜0.01; With model control group comparable group, * P＜0.05, * * P＜0.01.
By table 7 result as seen, with the normal control group relatively, ALT, AST, BUN and CREA obviously raise (P＜0.01 or P＜0.05) in the model control group mice serum; Compare with model control group, medicament high dose group mice serum ALT, AST that this technology and prescription are produced obviously reduce (P＜0.05), and BUN has the trend of reduction, but does not have significant difference (P＞0.05).
The above only is the specific embodiment of the best of the present invention, but architectural feature of the present invention is not limited thereto, and any those skilled in the art is in the field of the invention, and the variation of being done or modify all is encompassed among the claim of the present invention.
Claims (8)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100987597A CN101554406B (en) | 2009-05-14 | 2009-05-14 | Extraction process and formulation of mulberry cortex hypoglycemic medicinal active material |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100987597A CN101554406B (en) | 2009-05-14 | 2009-05-14 | Extraction process and formulation of mulberry cortex hypoglycemic medicinal active material |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101554406A true CN101554406A (en) | 2009-10-14 |
| CN101554406B CN101554406B (en) | 2012-08-08 |
Family
ID=41172788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009100987597A Active CN101554406B (en) | 2009-05-14 | 2009-05-14 | Extraction process and formulation of mulberry cortex hypoglycemic medicinal active material |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101554406B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102600245A (en) * | 2012-04-20 | 2012-07-25 | 南开大学 | Purification method and application of water-soluble alkaloid with alpha-glycosidase activity inhibition function in mulberry branch bark |
| CN105535112A (en) * | 2015-12-29 | 2016-05-04 | 浙江省农业科学院 | Extraction technology of hypoglycemic medicinal active substances of mulberry leaves and mulberries and formula |
| CN107213201A (en) * | 2017-05-11 | 2017-09-29 | 浙江省农业科学院 | The hypoglycemic active medicinal matter hydrolysis process of mulberry leaf, granatum and hypoglycemic agent |
| CN109350746A (en) * | 2018-10-19 | 2019-02-19 | 塔里木大学 | A kind of preparation method of 1-deoxynojirimycin sustained-release preparation with medicinal mulberry leaf polysaccharide as carrier |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100361674C (en) * | 2005-08-11 | 2008-01-16 | 原爱红 | Chinese medicine extract with function of reducing blood-sugar and preparing method |
| CN100464764C (en) * | 2006-03-08 | 2009-03-04 | 江苏大学 | Effective component composition and preparation method of mulberry leaves for lowering blood sugar |
| CN101224240A (en) * | 2007-01-17 | 2008-07-23 | 周应军 | Antidiabetics extract, preparing method and uses thereof |
| CN101209284A (en) * | 2007-12-24 | 2008-07-02 | 天津大学 | Method for continuously extracting active ingredients of alkaloids, flavonoids and polysaccharides from mulberry leaves |
| CN101278977B (en) * | 2008-03-31 | 2012-05-30 | 广州唐百服生物科技有限公司 | Method for extracting main active ingredients of mulberry leaves and application of extract |
| CN101412703B (en) * | 2008-11-17 | 2011-06-01 | 江苏科技大学 | A composite extraction process for co-production of mulberry leaf flavonoids, polysaccharides and alkaloids |
-
2009
- 2009-05-14 CN CN2009100987597A patent/CN101554406B/en active Active
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102600245A (en) * | 2012-04-20 | 2012-07-25 | 南开大学 | Purification method and application of water-soluble alkaloid with alpha-glycosidase activity inhibition function in mulberry branch bark |
| CN105535112A (en) * | 2015-12-29 | 2016-05-04 | 浙江省农业科学院 | Extraction technology of hypoglycemic medicinal active substances of mulberry leaves and mulberries and formula |
| CN107213201A (en) * | 2017-05-11 | 2017-09-29 | 浙江省农业科学院 | The hypoglycemic active medicinal matter hydrolysis process of mulberry leaf, granatum and hypoglycemic agent |
| CN109350746A (en) * | 2018-10-19 | 2019-02-19 | 塔里木大学 | A kind of preparation method of 1-deoxynojirimycin sustained-release preparation with medicinal mulberry leaf polysaccharide as carrier |
| CN109350746B (en) * | 2018-10-19 | 2021-07-23 | 塔里木大学 | A kind of preparation method of 1-deoxynojirimycin sustained-release preparation with medicinal mulberry leaf polysaccharide as carrier |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101554406B (en) | 2012-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103285231A (en) | Medicine composition for diabetes adjunctive therapy and preparation method thereof | |
| CN111358839B (en) | Formula granules of polygonum capitatum and preparation method thereof | |
| CN102512482A (en) | Euonymus alatus extract, blood-sugar-reducing activity thereof and application of euonymus alatus extract to preparation of products for reducing blood sugar | |
| CN101554406A (en) | Extraction process and formulation of mulberry cortex hypoglycemic medicinal active material | |
| CN112741851A (en) | Method for extracting sparrow tea extract by eutectic solvent method and preparation and application of granules | |
| CN102319357B (en) | Lipid-lowering dispersible tablets and preparation technology thereof | |
| CN102309705B (en) | Medicine for reducing serum uric acid, preparation method thereof and purpose thereof | |
| CN102224924B (en) | Sea cucumber saponin-containing composition and its application in foods and drugs | |
| CN114081906A (en) | Traditional Chinese medicine composition for treating constipation and preparation method thereof | |
| CN102512438A (en) | Application of pseudostellaria polysaccharide in food for preventing and treating diabetes mellitus as well as health-caring | |
| CN103432420B (en) | A kind of Chinese medicine composition for the treatment of diabetes and preparation method thereof and detection method | |
| CN101757391B (en) | Medicine composition for treating cardio-cerebral-vascular diseases and preparation method and application thereof | |
| CN102266480B (en) | Bulbus fritilariae snow pear capsules and preparation method thereof | |
| CN102068475A (en) | Application and blood-sugar lowering effective part of trapa acornis nakano shell as well as extraction method of blood-sugar lowering effective part | |
| CN101780124B (en) | A kind of Lonely Thousand Miles Extract and its preparation method and application | |
| CN102258570B (en) | Composition with activity of inhibiting α-glucosidase and preparation method thereof | |
| CN104548016A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating hyperuricemia | |
| CN103461980A (en) | Health food with function of adjusting blood fat | |
| CN102204985A (en) | A kind of composite lychee kernel hypoglycemic granule and preparation method thereof | |
| CN107213201A (en) | The hypoglycemic active medicinal matter hydrolysis process of mulberry leaf, granatum and hypoglycemic agent | |
| CN102885847A (en) | Novel uses of camellia oleifera cake polysaccharide | |
| CN102224931A (en) | Composition assisting in reduction of blood sugar | |
| CN102233084B (en) | Chinese medicinal composition for treating prostatitis and preparation method thereof | |
| CN101584828B (en) | Preparation for Chinese medicinal composition for clearing lung-heat | |
| CN105535070A (en) | Medicine composition for treating diabetes and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20091014 Assignee: Xinchang Hongwei Biotechnology Co., Ltd. Assignor: Zhejiang Academy of Agricultural Sciences Contract record no.: 2019330000063 Denomination of invention: Extraction process and formulation of mulberry cortex hypoglycemic medicinal active material Granted publication date: 20120808 License type: Exclusive License Record date: 20190618 |